1. Giapreza is an injection that increases blood pressure in adults with septic or other distributive shock.
2. Ixifi, Pfizer’s biosimilar version of Johnson & Johnson’s immunosuppressive drug Remicide, is intended to treat rheumatoid arthritis, Crohn’s disease and plaque psoriasis.
3. A novel gene therapy, Luxturna, treats a rare form of inherited vision loss that can result in complete blindness.
4. Nucala, a drug that treats severe asthma, is now approved to treat a rare autoimmune disease, eosinophilic granulomatosis with polyangiitis, which causes vasculitis, an inflammation in the wall of blood vessels.
6. Steglatro, approved to treat Type 2 diabetes, is a SGLT2 inhibitor, which works by causing patients to expel excess glucose through their urine.
More articles on supply chain:
Pfizer authorizes $10B share buyback
Two months after approval, Gilead’s ‘breakthrough’ cancer drug given to just a handful of patients
FDA launches website to improve management of antibiotic use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
